

	<b>Stroke</b>		<b>MI</b>
<b>Label</b>	Primary Model	Sensitivity Analysis	Primary Model
<b>Source</b>	Primary Baseline Stroke Model	Sensitivity Baseline Stroke Model	Primary Baseline MI Model
<b>Covariates</b>	Goodney et al <sup>19</sup>	Rothwell et al <sup>20</sup>	Lee et al <sup>14</sup>
	Qualifying Event: Stroke/TIA		Ischemic Heart Disease
	Age > 70	Sex	Congestive Heart Failure
	Contralateral Occlusion	Baseline Blood Pressure	History of Stroke
	Heart Failure		Insulin requiring Diabetes
			Creatinine > 2.0
	<b>Treatment Models</b>		
	<b>Stroke</b>	<b>MI</b>	
<b>Label</b>	Primary Model	Sensitivity Analysis	Primary Model
<b>Outcome</b>	Primary Stroke Treatment Model	Sensitivity Stroke Treatment Model	Primary MI Treatment Model
<b>Covariates</b>	Perioperative Stroke/Death	Perioperative Stroke/Death	Perioperative MI
	Primary Baseline Stroke Linear Predictor	Sensitivity Baseline Stroke Linear Predictor	Primary Baseline MI Linear Predictor
	Treatment (CEA vs. CAS)	Treatment (CEA vs. CAS)	Treatment (CEA vs. CAS)
	Symptomatic Status	Symptomatic Status Interaction between Treatment and Sensitivity	
		Baseline Stroke Linear Predictor	

Supplemental Table 1: Summary of the modeling approach

	<b>CEA</b> (n = 65,252)	<b>CAS</b> (n = 11,017)
Age mean(SD)	70.4 ( 9.6)	69.0 (11.3)
Female N(%)	25,845 (39.6%)	3,805 (34.5%)
Symptomatic N(%)	20,887 (32.0%)	1,082 ( 9.8%)
Diabetes N(%)	23,011 (35.3%)	3,981 (36.1%)
CHF N(%)	4,193 ( 6.4%)	871 ( 7.9%)
CAD N(%)	11,581 (17.7%)	2,004 (18.2%)
Creatinine mg/dl	1.1 ( 0.5)	1.1 ( 0.4)
Contralateral Occlusion N(%)	4,083 ( 6.3%)	755 ( 6.9%)

**Supplemental Table 2: Summary of the SVS-VQI CEA/CAS Population**